Abbott kicks off deep-brain stimulation trial in treatment-resistant depression
Abbott has launched a pivotal clinical trial to see if its deep-brain stimulation approach can make headway against treatment-resistant depression.
All Posts in "News Team"
Moderna’s mpox vaccine prevents severe symptoms in monkeys compared to Bavarian Nordic’s Jynneos
A new type of mpox, clade Ib, has been spreading rapidly within the Democratic Republic of Congo and leaking outside the African nation’s borders since Sept. 2023. In response, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern (PHEIC) last month, the second such declaration for an mpox variant in the past two years.
Athira’s phase 2/3 Alzheimer’s trial falls short, sinking stock
Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up the biotech’s stock price.
BioAge files for IPO, plans pair of midstage obesity trials
After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market.
ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in tow
Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers like Regeneron joining the artillery as the biotech sets out to build the biggest—and best—house on the block.
Eli Lilly bets $1B in biobucks on Haya to scour dark genome for obesity targets
Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets.
Aelis’ cannabis use drug flunks phase 2b, driving Indivior to rethink $100M option
Aelis Farma’s hopes of securing a quick, positive decision on a $100 million option payment have gone up in smoke. The French biotech reported the failure of its phase 2b cannabis use disorder (CUD) study Wednesday, prompting its partner Indivior to say it doesn’t currently expect to exercise its option.
Planet Labs Shares Drop After 4Q Outlook, 3Q Results Miss Estimates
Shares of Planet Labs on Monday dropped after the company provided a guidance for the fourth quarter that missed analysts expectations following weaker-than-expected third-quarter results.
Gold prices head for highest finish in over 2 weeks
Gold prices moved higher on Monday, on track to settle at their highest in just over two weeks after touching an intraday high of $2,700 an ounce.
Nvidia Drags Wall Street From Its Records as Oil and Gold Rise
A slide for market superstar Nvidia helped pull U.S. stock indexes down from their records
PharmaLegacy acquires BTS Research in hopes of becoming a ‘highly competitive global CRO’
Exact Sciences shows off early colorectal cancer blood test data
Lantheus’ phase 3 radiotherapy readout not enough to topple Pluvicto, say analysts
Boehringer’s phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Kairos goes public with $6M IPO to fund trials of lead cancer drug
Amgen and Merck become first industry partners of academic clinical trial diversity initiative
Novo Nordisk’s latest RNA deal involves $530M biobucks to sing in Korro’s opera
Bristol Myers axes Immatics’ bispecific after $150M bet
Wall Street Rises at the Start of a Holiday-Shortened Week
Nissan and Honda to Attempt a Merger That Would Create the World’s No. 3 Automaker